Hamden, CT, United States of America

Michael Brands



Average Co-Inventor Count = 11.7

ph-index = 3

Forward Citations = 17(Granted Patents)


Location History:

  • Hamden, CT (US) (2006 - 2010)
  • Wuppertal, DE (2009 - 2012)

Company Filing History:


Years Active: 2006-2012

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Michael Brands: Innovator in Pharmaceutical Chemistry

Introduction

Michael Brands is a notable inventor based in Hamden, CT (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for treating hyper-proliferative disorders.

Latest Patents

Michael Brands holds 5 patents that showcase his innovative work. His latest patents include "Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis." This invention focuses on pyrrolotriazine compounds, pharmaceutical compositions containing these compounds, and their application in preventing and treating hyper-proliferative disorders and diseases linked to angiogenesis. Another significant patent is for "Pyrimidine derivatives for treatment of hyperproliferative disorders." This patent describes pyrimidine derivatives that can be utilized in pharmaceutical compositions for treating hyper-proliferative diseases such as cancer.

Career Highlights

Throughout his career, Michael Brands has worked with prominent companies in the pharmaceutical industry, including Bayer Pharmaceuticals Corporation and Bayer Healthcare LLC. His work has contributed to advancements in medical treatments and therapies.

Collaborations

Michael has collaborated with notable colleagues, including Julie A Dixon and Wenlang Fu, enhancing the impact of his research and innovations.

Conclusion

Michael Brands is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable patents aimed at treating serious medical conditions. His contributions continue to influence the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…